troglitazone has been researched along with Osteoporosis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, S | 1 |
| Takeuchi, Y | 1 |
| Fukumoto, S | 1 |
| Fujita, H | 1 |
| Nakano, T | 1 |
| Fujita, T | 1 |
1 trial available for troglitazone and Osteoporosis
| Article | Year |
|---|---|
Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density; Chromans; Collagen; Collagen Type I; Di | 2003 |